Novavax Management

Management criteria checks 1/4

Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $7.30M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth $402.55K. The average tenure of the management team and the board of directors is 1.8 years and 4.3 years respectively.

Key information

John Jacobs

Chief executive officer

US$7.3m

Total compensation

CEO salary percentage9.1%
CEO tenure1.8yrs
CEO ownership0.03%
Management average tenure1.8yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Oct 31

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

Aug 13

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Jul 26

Novavax: New Chapter, Questions Remain

Jun 20

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14
Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13
Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06
Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

CEO Compensation Analysis

How has John Jacobs's remuneration changed compared to Novavax's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$285m

Jun 30 2024n/an/a

-US$294m

Mar 31 2024n/an/a

-US$399m

Dec 31 2023US$7mUS$663k

-US$545m

Compensation vs Market: John's total compensation ($USD7.30M) is above average for companies of similar size in the US market ($USD5.50M).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


CEO

John Jacobs (57 yo)

1.8yrs

Tenure

US$7,301,009

Compensation

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...


Leadership Team

NamePositionTenureCompensationOwnership
John Jacobs
President1.8yrsUS$7.30m0.030%
$ 402.6k
John Trizzino
President & COOless than a yearUS$1.88m0.018%
$ 239.7k
James Kelly
Executive VP3.3yrsUS$1.50m0.0090%
$ 122.2k
Mark Casey
Executive VPless than a yearUS$1.53mno data
Richard Crowley
Executive VP & COO1.8yrsno datano data
Troy Morgan
Senior VPno datano datano data
Erika Trahan
Associate Director of Investor & Public Relations6.6yrsno datano data
Ian Watkins
Executive VP & Chief Human Resources Officer1.3yrsno datano data
Silvia Taylor
Executive VP and Chief Corporate Affairs & Advocacy Officer2.8yrsno datano data
Robert Walker
Senior VP & Chief Medical Officerno datano datano data
Elaine O'Hara
Executive VP & Chief Strategy Officer1.8yrsno data0.0089%
$ 120.5k
Ruxandra Draghia-Akli
EVP and Head of Research & Developmentno datano datano data

1.8yrs

Average Tenure

59.5yo

Average Age

Experienced Management: NVAX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John Jacobs
President1.8yrsUS$7.30m0.030%
$ 402.6k
David Mott
Independent Director4.4yrsUS$187.53k0.032%
$ 427.5k
Richard Douglas
Independent Director14.8yrsUS$189.53k0.027%
$ 372.0k
Margaret McGlynn
Independent Director3.9yrsUS$185.02k0.0065%
$ 88.7k
Gregg Alton
Independent Director4.1yrsUS$175.28k0.0065%
$ 88.7k
Rachel King
Independent Director6yrsUS$174.55k0.012%
$ 160.2k
Richard Rodgers
Independent Director2.1yrsUS$191.78k0.0065%
$ 88.7k
James Young
Independent Chairman of the Board14.6yrsUS$222.53k0.039%
$ 523.2k

4.3yrs

Average Tenure

62yo

Average Age

Experienced Board: NVAX's board of directors are considered experienced (4.3 years average tenure).